BridgeBio Pharma Goodwill and Intangible Assets 2018-2024 | BBIO
BridgeBio Pharma goodwill and intangible assets from 2018 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
BridgeBio Pharma Annual Goodwill and Intangible Assets
(Millions of US $) |
| 2023 |
$26 |
| 2022 |
$29 |
| 2021 |
$45 |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Goodwill and Intangible Assets
(Millions of US $) |
| 2024-09-30 |
$25 |
| 2024-06-30 |
$25 |
| 2024-03-31 |
$26 |
| 2023-12-31 |
$26 |
| 2023-09-30 |
$27 |
| 2023-06-30 |
$28 |
| 2023-03-31 |
$28 |
| 2022-12-31 |
$29 |
| 2022-09-30 |
$29 |
| 2022-06-30 |
$30 |
| 2022-03-31 |
$30 |
| 2021-12-31 |
$45 |
| 2021-09-30 |
$46 |
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
